golidocitinib (DZD4205) / Dizal Pharmaceutical - LARVOL DELTA

Golidocitinib Plus Brentuximab Vedotin for Brentuximab Vedotin-Refractory/Relapsed Advanced Folliculotropic Mycosis Fungoides and Sézary Syndrome: A Retrospective Cohort Study (EADV 2026) - No abstract available

Late-breaking abstract • Metastases • Retrospective data • Cutaneous T-cell Lymphoma • Dermatology • Mycosis Fungoides • Oncology • Sezary Syndrome

GOLIDOCITINIB IN TREATING REFRACTORY OR RELAPSED PERIPHERAL T-CELL LYMPHOMA: PRIMARY ANALYSIS OF THE MULTINATIONAL PIVOTAL STUDY RESULTS (JACKPOT8) (ICML 2023) - P2 | "Golidocitinib demonstrated its potential as a novel targeted therapy for the treatment of r/r PTCL. The updated data will be presented at the conference. Encore Abstract—previously submitted to ASCO 2023"

Hematological Malignancies • Lymphoma • Oncology • Peripheral T-cell Lymphoma • JAK1

Golidocitinib in treating refractory or relapsed peripheral T-cell lymphoma: Primary analysis of the multinational pivotal study results (JACKPOT8). (ASCO 2023) - P2 | "Golidocitinib demonstrated its potential as a novel targeted therapy for the treatment of r/r PTCL. The updated data will be presented at the conference. Clinical trial information: NCT04105010."

Hematological Disorders • Hematological Malignancies • Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • JAK1

Efficacy and safety of a JAK1 inhibitor for relapsed/refractory large granular lymphocytic leukemia (PubMed, Zhonghua Xue Ye Xue Za Zhi) - "All remaining DAEs were grade 1-2. Golidocitinib monotherapy showed activity in patients with relapsed/refractory LGLL, with a rapid onset of response and a manageable short-term safety profile."

Journal • Retrospective data • Hematological Disorders • Hematological Malignancies • Leukemia • Neutropenia • Oncology • Thrombocytopenia

Real-world efficacy and safety of golidocitinib in 3 patients with relapsed/refractory peripheral T-cell lymphoma. (PubMed, Front Oncol) - "Golidocitinib exhibits promising efficacy and a tolerable safety profile in R/R PTCL, including rare subtypes, supporting its role as a valuable therapeutic option. Larger cohorts are needed for further validation."

Journal • Real-world evidence • Hematological Disorders • Hematological Malignancies • Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma

Golidocitinib as salvage therapy before allogeneic hematopoietic stem cell transplantation in refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. (PubMed, Haematologica) - "Not available."

Journal • Bone Marrow Transplantation • Epstein-Barr Virus Infections • Hemophagocytic lymphohistiocytosis • Immunology • Rare Diseases • Transplantation

Golidocitinib Plus Anthracycline-based Therapy for Untreated Nodal T-follicular Helper (TFH) Cell Lymphoma (clinicaltrials.gov) - P2 | N=47 | Not yet recruiting | Sponsor: Sun Yat-sen University

New P2 trial • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Oncology

Efficacy and Safety of Golidocitinib for Rapidly Progressive Interstitial Lung Disease (clinicaltrials.gov) - P2 | N=60 | Not yet recruiting | Sponsor: Peking Union Medical College Hospital

New P2 trial • Interstitial Lung Disease • Pulmonary Disease • Respiratory Diseases

The JAK1 Inhibitor Golidocitinib Boosts Therapeutic Potency of DLL3-Targeted CAR-T Therapy for Small Cell Lung Cancer. (PubMed, Pharmacol Res) - "When combined with anti-DLL3 CAR-T therapy, golidocitinib significantly augmented anti-tumor efficacy in both in vitro cytotoxicity assays and in vivo models, without obvious organ toxicity. These findings collectively demonstrate the dual anti-tumor effects of golidocitinib, thus providing a novel and promising strategy for SCLC treatment."

IO biomarker • Journal • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • DLL3

G08: New Genotype-guided Treatment in Newly Diagnosed PTCL (clinicaltrials.gov) - P1/2 | N=108 | Not yet recruiting | Sponsor: Ruijin Hospital

New P1/2 trial • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma

Golidocitinib for Folliculotropic Mycosis Fungoides. (PubMed, JAMA Dermatol) - No abstract available

Journal • Cutaneous T-cell Lymphoma • Dermatology • Mycosis Fungoides • Oncology

Efficient chemical reprogramming of human T cells into functional megakaryocytes and platelets. (PubMed, Sci Adv) - "This method used a five-small molecule cocktail containing a reprogramming booster, AZD4205, to promote erasure of T cell identity and facilitate fate transition toward MKs...Single-cell RNA sequencing further revealed that iMKs were heterogeneous with distinct functional profiles, including cycling, immune, and thrombopoiesis-biased MKs. Our findings highlight an optimized chemical reprogramming strategy that enables efficient conversion of T cells to MKs, providing a practical and convenient approach to generating clinically relevant MKs and platelets."

Journal

Golidocitinib-Based Therapy in Relapsed/Refractory Mycosis Fungoides and Sézary Syndrome: A Real-World Retrospective Analysis (BAD 2026) - "The majority of patients (n = 9, 90%) received combination therapy, all incorporating brentuximab vedotin (BV), while one patient received monotherapy. This pioneering realworld study demonstrates that golidocitinib-based regimens offer favourable clinical efficacy in patients with relapsed or refractory MF or SS, including those refractory to prior BV. Subsequent prospective trials are warranted to further validate these combination strategies."

Real-world • Real-world evidence • Retrospective data • Cutaneous T-cell Lymphoma • Cytomegalovirus Infection • Dermatology • Hematological Malignancies • Infectious Disease • Lymphoma • Mycosis Fungoides • Oncology • Peripheral T-cell Lymphoma • Sezary Syndrome • T Cell Non-Hodgkin Lymphoma • Thrombocytopenia • CD4 • JAK3

GOLIDOCITINIB、MITOXANTRONE HYDROCHLORIDE LIPOSOME、CHIDAMIDE AND PREDNISONE (GO-MCP) IN RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA:A REAL-WORLD RETROSPECTIVE STUDY (EHA 2026) - "Of note, one PTCL patient with CNS relapse after five cycles of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) and subsequent progression on second ‑ line methotrexate/temozolomide with intrathecal therapy achieved CR on PET ‑ CT after 7 cycles of Go ‑ MCP.This result indicated promising efficency in CNS relapse patients and in mitoxantrone exposure patients.Two enrolled patients have proceeded to autologous stem cell transplantation following Go-MCP treatment, with the longest progression- free survival (PFS) reaching 190 days to date, demonstrating deep remission of Go-MCP regimen. Grade 3 infections occurred in five patients (71.4%, including three of pulmonary infection, two of skin infection, and one of abdominal infection); No hemolysis or other hematolymphatic disorders were observed. . Summary/Conclusion In conclusion, the Go ‑ MCP regimen demonstrates preliminary efficacy and a generally manageable safety profile in patients with R/R PTCL, but..."

Real-world • Real-world evidence • Retrospective data • Hematological Malignancies • Herpes Zoster • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Peripheral T-cell Lymphoma • Respiratory Diseases • T Cell Non-Hodgkin Lymphoma • Varicella Zoster

HIGHLY SELECTIVE JAK1 INHIBITION FOR HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS IN MURINE MODELS WITH PRELIMINARY CLINICAL INVESTIGATION (EHA 2026) - "Using murine models of primary ( Prf1 −/− mice infected with LCMV) and secondary (CpG-induced) HLH, the novel agent golidocitinib with high JAK1 selectivity was evaluated relative to unselective JAK inhibitors ruxolitinib (JAK1/2) and gecacitinib (pan-JAK). Single-cell RNA sequencing of patient samples further pinpointed activated CST7 ⁺ /G0S2 ⁺ neutrophils as potential targets, which exhibited reduced JAK-STAT activity following golidocitinib treatment, alongside its dual therapeutic mechanism of attenuating inflammation crosstalk and eliminating malignant T-cell clones in t-HLH. Summary/Conclusion These findings highlight the therapeutic advantage of highly selective JAK1 inhibition and support golidocitinib as a promising candidate for HLH."

Preclinical • Hemophagocytic lymphohistiocytosis • Immunology • Rare Diseases • G0S2 • JAK1 • PRF1 • STAT1 • STAT3

GEMSTONE: Golidocitinib in Patients With Mycosis Fungoides/Szary Syndrome and T-Cell Large Granular Lymphocytic Leukemia (clinicaltrials.gov) - P2 | N=24 | Not yet recruiting | Sponsor: Washington University School of Medicine

New P2 trial • Cutaneous T-cell Lymphoma • Dermatology • Hematological Malignancies • Leukemia • Lymphoma • Mycosis Fungoides • Non-Hodgkin’s Lymphoma • Oncology • Sezary Syndrome • T-Cell Large Granular Lymphocyte Leukemia

REAL-WORLD TREATMENT PATTERNS AND OUTCOMES IN ADVANCED-STAGE MYCOSIS FUNGOIDES: A 26-CASE RETROSPECTIVE COHORT STUDY FROM CHINA (EHA 2026) - "Most used agents: BV (81%, 21), HDAC inhibitors (58%, 15), golidocitinib (46%, 12), liposomal mitoxantrone (31%, 8),reflecting highly individualized sequencing in real-world practice. All 3 FMF patients receiving golidocitinib remain alive and progression-free. . Summary/Conclusion This real-world cohort with extended follow-up demonstrates: 1) BV is highly active in advanced MF, with post-BV interferon maintenance offering durable disease control; 2) Post-BV options remain limited with modest efficacy; 3) Golidocitinib produced durable responses in FMF, suggesting JAK inhibition warrants prospective study in this subtype."

HEOR • Metastases • Real-world • Real-world evidence • Retrospective data • Cutaneous T-cell Lymphoma • Dermatology • Mycosis Fungoides • Oncology • TNFRSF8

GOLIDOCITINIB AND LIPOSOMAL MITOXANTRONE FOR RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA: PRELIMINARY SAFETY AND EFFICACY FROM A MULTI-CENTER RETROSPECTIVE STUDY (EHA 2026) - "Summary/Conclusion The combination of golidocitinib and liposomal mitoxantrone demonstrates a manageable safety profile and promising preliminary efficacy in patients with R/R PTCL. A prospective Phase II study is ongoing to further validate these encouraging findings."

Retrospective data • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Peripheral T-cell Lymphoma • Respiratory Diseases • T Cell Non-Hodgkin Lymphoma • Thrombocytopenia • ALK

Beyond Romidepsin: Novel Therapeutic Targets and Emerging Strategies for Relapsed and Refractory Peripheral T-Cell Lymphoma. (PubMed, Clin Lymphoma Myeloma Leuk) - "Following romidepsin's withdrawal from the R/R PTCL indication in 2021, the only FDA-approved agents are belinostat and pralatrexate, and Brentuximab Vedotin...EZH2 inhibitors represent a mechanistically novel class: valemetostat produced an ORR of 43.7% with a median duration of response of 11.9 months. JAK/STAT inhibitors, including golidocitinib (ORR 44.3%) and cerdulatinib (ORR 51.9% in AITL/TFH), show subtype-selective activity. Rational combinations yield superior efficacy: duvelisib plus romidepsin achieved ORR of 56% (CR 44%), while azacitidine combined with romidepsin produced ORR of 61% (CR 48%), particularly in TFH-phenotype disease (ORR 80%)...The Ro-CHOP trial's failure in unselected populations, contrasted with efficacy signals in nTFHL subsets, underscores a critical lesson: PTCL is not one disease, and future trial designs must incorporate biomarker-driven enrichment strategies to advance precision therapeutics. Improved outcomes can be expected..."

Journal • Review • Gene Therapies • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • DNMT3A • KLRD1 • RHOA • TET2

BRENTUXIMAB VEDOTIN COMBINED WITH CHIDAMIDEIN AND MITOXANTRONE HYDROCHLORIDE LIPOSOME OR GOLIDOCITINIB IN RELAPSED/REFRACTORY CD30-POSITIVE CUTANEOUS T-CELL LYMPHOMA: A REAL-WORLD STUDY DESIGN (EHA 2026) - "Among these, BV, a CD30-directed ADC, combined with chidamide, an HDAC inhibitor, has been proven to have a synergistic effect and recommended in relapsed/refractory (R/R) settings. Summary/Conclusion This study is designed to provide robust evidence for the combination therapy (BV plus chidamidein and MIT-LIP or golidocitinib) in RW settings, potentially offering a valuable therapeutic strategy in patients with R/R CD30+ CTCL. The study is recruiting, with preliminary results available in subsequent reports."

Clinical • Real-world • Real-world evidence • Cutaneous T-cell Lymphoma • Hematological Malignancies • Lymphoma • Mycosis Fungoides • Sezary Syndrome • T Cell Non-Hodgkin Lymphoma • TNFRSF8

COMBINATION OF GOLIDOCITINIB WITH CHIDAMIDE FOR PERIPHERAL T-CELL LYMPHOMA: POSSIBLE MECHANISMS AND THERAPEUTIC POTENTIAL IN INHIBITING TUMOR PROLIFERATION AND MODULATING THE IMMUNE MICROENVIRONMENT (EHA 2026) - "These *ndings are re)ected in the clinical responses observed across all four types of peripheral T-cell lymphoma (PTCL) patients, including cases of refractory disease achieving complete remission. This laboratory-to-clinical consistency provides evidence supporting the combination therapy as a promising new treatment paradigm for PTCL."

Hematological Malignancies • Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma

GOLIDOCITINIB MONOTHERAPY IN HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS: A PROSPECTIVE, SINGLE-ARM CLINICAL TRIAL TO EVALUATE EFFICACY AND SAFETY (JACKPOT11) (EHA 2026) - P2/3 | "Two patients withdrew due to progression of their primary disease. Summary/Conclusion This interim analysis suggests that Golidocitinib monotherapy demonstrates promising early efficacy and favorable safety profile in patients with HLH, supporting further investigation of this targeted approach."

Clinical • Monotherapy • Cytomegalovirus Infection • Epstein-Barr Virus Infections • Hematological Disorders • Hematological Malignancies • Hemophagocytic lymphohistiocytosis • Immunology • Infectious Disease • Lymphoma • Pancreatitis • Rare Diseases • Thrombocytopenia • IL6 • JAK1 • TNFA

GENOMIC SIGNATURES GUIDED COMBINATION THERAPY OF TAZEMETOSTAT PLUS LINPERLISIB OR GOLIDOCITINIB IN RELAPSED AND REFRACTORY PERIPHERAL T-CELL LYMPHOMA PATIENTS (EHA 2026) - "A phase 2 study showed Tazemetostat (EZH2 inhibitor) plus Amdizalisib (PI3K inhibitors) achieved objective response rate (ORR) 60.7% in R/R PTCL, remarkably with 100% complete response rate(CRR) in 5 patients with TET2/RHOA co-mutations 1 . Based on preliminary efficacy results, this study may increase the sample size for further exploration later. Summary/Conclusion ."

Clinical • Combination therapy • Hematological Malignancies • Lymphoma • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • EZH2 • RHOA • TET2

GOLIDOCITINIB-BASED COMBINATION THERAPY AS FIRST-LINE TREATMENT FOR PTCL: A SINGLE-CENTER RETROSPECTIVE ANALYSIS (JACKPOT55) (EHA 2026) - "Summary/Conclusion Golidocitinib combined with CHOP-like chemotherapy regimens demonstrated encouraging anti-tumor efficacy and clinically manageable safety profile in patients with newly diagnosed PTCL. Prospective studies to further validate these findings are warranted."

Combination therapy • Retrospective data • Cytomegalovirus Infection • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Herpes Simplex • Infectious Disease • Leukopenia • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Peripheral T-cell Lymphoma • Pneumonia • Respiratory Diseases • T Cell Non-Hodgkin Lymphoma • Thrombocytopenia • JAK1

MINE REGIMEN COMBINED WITH TARGETED AGENTS IN RELAPSED/REFRACTORY ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA: A PRELIMINARY EXPLORATORY RETROSPECTIVE STUDY INTEGRATED WITH NEXT-GENERATION SEQUENCING (EHA 2026) - "The MINE regimen (ifosfamide, mitoxantrone, etoposide) is a salvage option, but data on its combination with targeted agents (azacitidine, chidamide, golidocitinib, tazemetostat, enasidenib, ruxolitinib) in rrAITL remain limited. High tumor mutational burden was associated with early progression and poor outcome, suggesting a potential predictive biomarker for treatment selection. These preliminary findings warrant validation in larger prospective studies."

Biomarker • Next-generation sequencing • Retrospective data • Tumor mutational burden • Gastroenterology • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • Thrombocytopenia • DNMT3A • IDH2 • KMT2D • PLCG1 • RHOA • STAT3 • TET2 • TMB • TP53